HIV 환자의 알코올 사용 장애에 대한 라벨 외 약물: 파일럿 연구 2 (HARP)
HIV 환자의 알코올 사용 장애에 대한 비허가 약물의 타당성, 수용 가능성 및 예비 효능: 공개 예비 연구
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
연구 개요
상세 설명
This is a series of three open-label pilot studies that consist of a 12-week intervention including off-label use of medication with MM and a clinical pharmacist-delivered behavioral intervention to treat AUD. Participants will receive counseling that incorporates brief feedback and advice with motivational enhancement techniques to assist the participant in changing their behaviors with respect to alcohol consumption and/or polypharmacy defined as taking five or more medications, particularly if those medications interact with alcohol. In addition, participants will be offered varenicline in the first pilot study. The rationale for utilizing an open-label pilot study design is to determine the feasibility, acceptability, safety, and preliminary efficacy of this intervention for the management of AUD. Participants will be interviewed with regards to their perspectives on feasibility and acceptability. They will be instructed to have medication bottles at study visits to assess medication adherence and will be assessed with readiness to change metrics and questions regarding quantity and frequency of alcohol use. Patients will also be asked to complete an AUDIT-C screen and the Alcohol Symptom Checklist at the start of the study period to screen for mild, moderate, or severe AUD. Several assessments including interviews and laboratory testing will be done at study visits.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Georgia
-
Decatur, Georgia, 미국, 30033
- Atlanta VA Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- diagnosed with HIV
- Receive care at the Atlanta VA Healthcare System
- Are age 18 or over
- Meet criteria for mild, moderate, or severe alcohol use disorder by the DSM-5 Alcohol Symptom Checklist and the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) screen
- Have evidence of significant alcohol use: PEth > 20ng/ml
- Currently smoking cigarettes
- Prescribed >=5 medications
- Have cell phone or reliable contact number
- Can provide written informed consent
Exclusion Criteria:
- Active engagement in formal alcohol treatment including medications for alcohol use disorder at the time of enrollment
- Self-report or laboratory test confirming pregnancy, nursing, or trying to conceive
- Life-threatening or unstable medical, surgical, or psychiatric condition that prohibits participation (including current or past intent to harm oneself or others within the prior 12 months and not receiving treatment
- Untreated moderate to severe opioid use disorder
- Residence out of state
- Inability to read or understand English
- History of serious hypersensitivity or adverse reaction to study medication
- Taking potentially interactive medication(s) (e.g. nicotine replacement therapy for varenicline pilot study)
- Already prescribed the pilot medication at the time of study recruitment
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Varenicline
Participants will receive a prescription for generic varenicline |
All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of participants who complete enrollment and duration of sessions
기간: 12 weeks
|
Proportion of participants who complete enrollment and duration of sessions to assess feasibility of study |
12 weeks
|
|
Number of sessions completed
기간: 12 weeks
|
Number of sessions completed to assess acceptability of study |
12 weeks
|
|
Adherence to Medication
기간: 12 weeks
|
Medication adherence will be measured by the number of prescriptions filled by electronic health record to assess acceptability of study |
12 weeks
|
|
Safety of study assessed by adverse events reporting
기간: 12 weeks
|
Safety will be assessed by the percentage of study participants who report adverse events |
12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy of study - change in self-reported alcohol use
기간: 12 weeks
|
Change in self-reported alcohol use (# of days of alcohol use and # of drinks per day) on the Timeline Followback. |
12 weeks
|
|
Efficacy of study - change in PEth (phosphatidylethanol) results
기간: 12 weeks
|
PEth is a biomarker for alcohol consumption. Change in PEth result from baseline PEth levels. |
12 weeks
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: E. Jennifer Edelman, MD, MHS, Yale University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2000033919_b
- 1P01AA029545-01 (미국 NIH 보조금/계약)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .